Using artificial intelligence as a discovery tool, researchers have discovered that the hormone melatonin could offer protection against both aging and Alzheimer’s disease (AD).

They say their study sets out a reproducible “AI-to-clinic” paradigm that can provide breakthroughs towards clinically effective therapeutics targeting the intertwined complexities of aging and AD.

The findings demonstrate how sophisticated computational frameworks such as machine learning, deep learning, and network-based analytics can systematically mine and interpret vast genomic, transcriptomic, and pharmacological datasets to revolutionize drug discovery.

“Our AI-driven methodological framework offers a transformative approach to overcoming traditional drug development barriers, opening new avenues for prec

See Full Page